Universal Beteiligungs und Servicegesellschaft mbH Reduces Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH reduced its stake in MoonLake Immunotherapeutics by 26.6%, selling 5,351 shares and holding 14,790 shares worth approximately $578,000.
• Several hedge funds, including FMR LLC and Paradigm Biocapital Advisors LP, have increased their holdings significantly in the past quarter, indicating strong institutional interest.
• MoonLake Immunotherapeutics reported earnings of ($0.63) per share, exceeding analyst expectations, with a consensus rating of "Moderate Buy" and an average target price of $73.14.

Universal Beteiligungs und Servicegesellschaft mbH lowered its position in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 26.6% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,790 shares of the company's stock after selling 5,351 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH's holdings in MoonLake Immunotherapeutics were worth $578,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of MLTX. Deutsche Bank AG increased its stake in MoonLake Immunotherapeutics by 59.8% in the fourth quarter. Deutsche Bank AG now owns 903 shares of the company's stock valued at $49,000 after acquiring an additional 338 shares during the last quarter. Birchview Capital LP acquired a new position in shares of MoonLake Immunotherapeutics in the 4th quarter valued at about $217,000. KLP Kapitalforvaltning AS bought a new position in shares of MoonLake Immunotherapeutics during the 4th quarter worth about $244,000. PEAK6 LLC acquired a new position in shares of MoonLake Immunotherapeutics during the fourth quarter valued at about $271,000. Finally, Mariner LLC bought a new stake in MoonLake Immunotherapeutics in the 4th quarter worth about $272,000. Institutional investors own 93.85% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on MLTX. Needham & Company LLC restated a "buy" rating and set a $66.00 price target on shares of MoonLake Immunotherapeutics in a research note on Tuesday, May 13th. Wedbush restated an "outperform" rating and set a $80.00 target price (up previously from $78.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday, May 13th. Redburn Atlantic raised shares of MoonLake Immunotherapeutics to a "hold" rating in a report on Monday, July 28th. The Goldman Sachs Group raised their price target on shares of MoonLake Immunotherapeutics from $74.00 to $82.00 and gave the company a "buy" rating in a report on Wednesday. Finally, Wolfe Research raised shares of MoonLake Immunotherapeutics from a "peer perform" rating to an "outperform" rating and set a $61.00 price target for the company in a report on Monday, May 19th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $74.43.

MoonLake Immunotherapeutics Price Performance

MoonLake Immunotherapeutics stock traded down $1.20 during mid-day trading on Wednesday, reaching $52.21. 300,707 shares of the company's stock traded hands, compared to its average volume of 484,802. The company has a quick ratio of 21.11, a current ratio of 21.11 and a debt-to-equity ratio of 0.18. MoonLake Immunotherapeutics has a 12-month low of $31.42 and a 12-month high of $58.26. The company has a market cap of $3.34 billion, a price-to-earnings ratio of -22.72 and a beta of 1.27. The stock has a 50 day moving average of $48.05 and a two-hundred day moving average of $43.00.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.87) earnings per share for the quarter, missing analysts' consensus estimates of ($0.73) by ($0.14). During the same quarter in the prior year, the company posted ($0.39) EPS. Equities analysts forecast that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current year.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.